Country: Irlanda
Lingwa: Ingliż
Sors: HPRA (Health Products Regulatory Authority)
Alendronic acid
Xeolas Pharmaceuticals Limited
M05BA; M05BA04
Alendronic acid
70 milligram(s)
Oral solution
Product subject to prescription which may be renewed (B)
Bisphosphonates; alendronic acid
Marketed
2011-02-25
Health┴Products┴Regulatory┴Authority 19┴November┴2021 CRN00CNRN Page┴1┴of┴9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bonasol┴Once┴Weekly┴70┴mg┴Oral┴Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each┴100┴ml┴single-dose┴contains┴70┴mg┴alendronic┴acid (as┴91.35┴mg┴sodium┴alendronate┴trihydrate) Excipients: Each┴dose┴(100┴ml)┴contains┴80┴mg┴methyl┴parahydroxybenzoate┴(E218),┴20┴mg┴propyl┴parahydroxybenzoate┴(E216)┴and┴6┴mg┴ Sunset┴Yellow┴(E110).┴ For┴a┴full┴list┴of┴excipients,┴see┴section┴6.1. 3 PHARMACEUTICAL FORM Oral┴solution. Orange┴coloured┴opalescent┴solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment┴of┴post-menopausal┴osteoporosis. Alendronic┴acid┴reduces┴the┴risk┴of┴vertebral┴and┴hip┴fractures. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology For┴oral┴administration. The┴recommended┴dosage┴is┴one┴70mg┴unit-dose┴(100┴ml)┴once┴weekly. The┴optimal┴duration┴of┴bisphosphonate┴treatment┴for┴osteoporosis┴has┴not┴been┴established. ┴The┴need┴for┴continued┴ treatment┴should┴be┴re-evaluated┴periodically┴based┴on┴the┴benefits┴and┴potential┴risks┴of┴Bonasol┴Once┴weekly┴70┴mg┴Oral┴ Solution┴on┴an┴individual┴patient┴basis,┴particularly┴after┴5┴or┴more┴years┴of┴use. Method of Administration _To permit adequate absorption of alendronic acid_ ┴ _Bonasol Once Weekly 70 mg Oral Solution_┴must┴be┴taken┴at┴least┴30┴minutes┴before┴the┴first┴food,┴beverage,┴or┴medicinal┴ product┴of┴the┴day┴with┴plain┴water┴only.┴Other┴beverages┴(including┴mineral┴water),┴food┴and┴some┴medicinal┴products┴are┴ likely┴to┴reduce┴the┴absorption┴of┴alendronic┴acid┴(see┴Section┴4.5). _To facilitate delivery to the stomach and thus reduce the potential for Aqra d-dokument sħiħ